Education Core

教育核心

基本信息

批准号：
10246843
负责人：
Christopher M. Sistrunk
金额：
$ 3.83万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-02 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10246843
关键词：
African American American Antineoplastic Agents Applications Grants Award Basic Science Bioinformatics Biology California City of Hope Comprehensive Cancer Center Clinical Clinical Trials Collaborations Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility Data Drug Design Drug Targeting Eating Education Education and Outreach Educational Curriculum Engineering Ethics European Exposure to Faculty Funding Goals Health Sciences Hispanic Americans Hispanic-serving Institution Inequality Institution Investments Joints Laboratories Latino Master&apos s Degree Medical Students Mentorship Methods NCI Center for Cancer Research Participant Patients Persons Pharmaceutical Preparations Phase Phase I Clinical Trials Phase II Clinical Trials Physicians Precision Medicine Initiative Reporting Research Research Infrastructure Research Personnel Resources Rotation Running Scientist Societies Students System Testing Therapeutic Clinical Trial Training Training Programs Translating United States United States Food and Drug Administration United States National Institutes of Health Universities Visit anticancer research cancer health disparity career chimeric antigen receptor T cells clinical translation community clinic community partnership curriculum development disparity elimination diversity and equity diversity and inclusion drug development drug discovery drug repurposing education research education resources ethnic diversity experience first-in-human graduate student health disparity innovation manufacturing facility medical schools minority communities nanotherapy news next generation novel therapeutics outreach precision drugs precision medicine programs research and development screening social determinants stem cell therapy success summer research targeted agent undergraduate student virtual

项目摘要

Abstract: University of California at Riverside (UCR) is the newest medical school in the University of California system and a NIH-designated ISUPS institution. UCR's mandate is to serve SoCal's majority-minority communities and train the next generation of Latino/Hispanic-American and Black/African-American engineers, biologists, and physicians. City of Hope Comprehensive Cancer Center (CoH-CCC) is a Comprehensive Cancer Center whose 121 researchers have been awarded over $75M in NIH/NCI funding. CoH-CCC leads the world in academic drug discovery and has commercialized blockbusters drugs such as HumalinTM, HerceptinTM, and RituximabTM. CoH has world-class bioinformatics for drug design, extensive screening and synthetic capability, three onsite GMP-manufacturing facilities, and a robust clinical/translation Phase I program. Over the past 5 years 21 drugs have gone from R01 concept to first-in-man testing. The goal of the Collaborative Cancer Research Education Program (C-REP) is for UCR and CoH-CCC to develop the research experiences, curriculum, and outreach education resources necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. Aim 1: Research Experiences will provide tailored research experiences in cancer research and drug development. Aim 2: Curriculum Development will provide courses to introduce both UCR and CoH students and faculty to methods and innovation in drug development and the health science of disparities. Aim 3 Outreach Education and Resources will 1) expose early stage investigators to career opportunities drug development and clinical trials and 2) provide training and capacity building for fellows and faculty to translate their findings to drive drug discovery.

抽象的：加利福尼亚大学河滨分校（UCR）是加利福尼亚大学系统的最新医学院以及NIH指定的ISUPS机构。 UCR的任务是为SoCal的多数少数社区服务并培训下一代拉丁裔/西班牙裔美国人和黑人/非裔美国人工程师，生物学家，和医生。希望之城综合癌症中心（COH-CCC）是一个综合癌症中心他的121位研究人员获得了超过7500万美元的NIH/NCI资金。 COH-CCC领导着世界学术药物发现并已商业化的大片药物，例如Humalintm，Herseptintm和利妥昔单抗。 COH具有用于药物设计，广泛筛查和合成能力的世界一流的生物信息学，三个现场GMP制造设施和强大的临床/翻译阶段计划。在过去的5个 21年的药物已从R01概念到人类的第一名测试。协作癌症研究教育计划（C-REP）的目标是用于UCR和COH-CCC 开发研究经验，课程和外展教育资源，以开发下一代的治疗研究人员反映了内陆南加州的种族多样性。目的 1：研究经验将为癌症研究和药物提供量身定制的研究经验发展。 AIM 2：课程开发将提供介绍UCR和COH学生的课程以及对药物开发和差异健康科学的方法和创新的教师。目标3 外展教育和资源将1）暴露早期调查人员遇到职业机会药物开发和临床试验以及2）为研究员和教职员工提供培训和能力建设他们的发现是推动毒品发现的结果。